Results 81 to 90 of about 2,744,410 (300)

Translating whole‐genome doubling into precision medicine in cancer

open access: yesMolecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Drug-Induced Epigenetic Changes Produce Drug Tolerance

open access: yesPLoS Biology, 2007
Tolerance to drugs that affect neural activity is mediated, in part, by adaptive mechanisms that attempt to restore normal neural excitability. Changes in the expression of ion channel genes are thought to play an important role in these neural adaptations.
Wang, Yan   +4 more
openaire   +5 more sources

PANoptosis in the pathogenesis of myelodysplastic syndromes

open access: yesMolecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla   +4 more
wiley   +1 more source

Global network analysis of drug tolerance, mode of action and virulence in methicillin-resistant S. aureus [PDF]

open access: yes, 2011
Background: Staphylococcus aureus is a major human pathogen and strains resistant to existing treatments continue to emerge. Development of novel treatments is therefore important.
Barton, Geoffrey J   +30 more
core   +1 more source

Optimizing targeted therapy for metastatic melanoma: a combination of encorafenib and trametinib beyond standard protocols

open access: yesDermatology Reports
Only three combinations of BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) targeted therapies are marketed for the treatment of BRAF-mutated metastatic melanoma. The use of these combinations can be limited by the occurrence of severe adverse events (AEs)
François Pélouard   +4 more
doaj   +1 more source

ADP‐ribosylation: An emerging regulator of the epigenome

open access: yesMolecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho   +2 more
wiley   +1 more source

Training toolkit on drug policy advocacy.

open access: yes, 2013
This training toolkit has been developed by the International Drug Policy Consortium (IDPC) and the Eurasian Harm Reduction Network (EHRN) to build the capacity of civil society organisations for engaging with, and influencing, drug policy making ...

core  

NLRP3 inflammasome: a key driver of neuroinflammation and a novel therapeutic target for neuropathic pain [PDF]

open access: yesAnesthesia and Pain Medicine
Neuropathic pain represents a serious complication arising from a spectrum of disorders that precipitate lesions within the central and peripheral nervous systems. This disabling pain can persist for years, severely diminishing the quality of life of the
Zana Montazeri-Khosh   +6 more
doaj   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

open access: yesMolecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee   +3 more
wiley   +1 more source

‘Civil society involvement in drug policy’ webinar.

open access: yes, 2018
On 30th November 2018, Ana Liffey Drug Project hosted a webinar about Civil Society Involvement in Drug Policy. The event included interviews with: Anna Quigley (CityWide) Tony Duffin (Ana Liffey Drug Project) Aoife Frances (National Family Support ...

core  

Home - About - Disclaimer - Privacy